Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies

NCT04740424 is registered in ClinicalTrials.gov with invoX Pharma Limited as lead sponsor.

NCT NCT04740424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04740424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies
Lead sponsor
invoX Pharma Limited
Phase
Phase 1
Overall status
Recruiting
Start date
December 14, 2020
Completion date
October 30, 2027
Enrollment
260 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer